CAR-T cell. the long and winding road to solid tumors by D'Aloia, MARIA MICHELA et al.
D’Aloia et al. Cell Death and Disease  (2018) 9:282 
DOI 10.1038/s41419-018-0278-6 Cell Death & Disease
REV I EW ART ICLE Open Ac ce s s
CAR-T cells: the long and winding road to
solid tumors
Maria Michela D’Aloia1, Ilaria Grazia Zizzari2, Benedetto Sacchetti3, Luca Pierelli2 and Maurizio Alimandi1
Abstract
Adoptive cell therapy of solid tumors with reprogrammed T cells can be considered the “next generation” of cancer
hallmarks. CAR-T cells fail to be as effective as in liquid tumors for the inability to reach and survive in the
microenvironment surrounding the neoplastic foci. The intricate net of cross-interactions occurring between tumor
components, stromal and immune cells leads to an ineffective anergic status favoring the evasion from the host’s
defenses. Our goal is hereby to trace the road imposed by solid tumors to CAR-T cells, highlighting pitfalls and
strategies to be developed and refined to possibly overcome these hurdles.
Facts
● Unparalleled clinical efficacy has been demonstrated
using anti CD19-CAR-T cells to treat refractory B-
cell malignancies.
● Many are the challenges imposed by solid tumors for
a successful development of CAR T-cell
immunotherapy.
● Genetically modified T cells can be alternatively
generated using transposons systems (e.g., Sleeping
Beauty) to stably introduce CARs in T lymphocytes.
Open questions
● How CARs should be designed and engineered to be
effective in the treatment of solid tumors?
● Which strategies need to be developed and refined
to improve the balance between favorable and
unfavorable effects for better therapeutic benefits?
● What are the priorities for CAR-T cell therapy that
must be addressed as they concern safety and
efficacy?
● Can the use of genome editing techniques be helpful
in generating CAR-armed T lymphocytes suitable
for the treatment of solid tumors?
Introduction
T cells normally build poor or no response against
syngeneic transformed cells, (a) for their poor antigenicity,
(b) because transformed cells are not phenotypically for-
eign, and (c) for the generalized immunosuppressive
conditions often associated with cancer. For these rea-
sons, adequate immune responses against tumors have
seldom been observed, at least in patients treated with
chemotherapeutic agents1,2. These observations stimu-
lated oncologist and immunologists to boost and activate
the T-cell responses against tumor cells, attempts that
over the years, never accomplished straightforward clin-
ical results.
Recent knowledge shows that the immune system is kept
in shape through a delicate network of signaling pathways
delivered by T-cell activating receptors (accelerators) and
inhibitory receptors (brakes) to regulate the balance
between immune response and immune tolerance3–5. This
established the platform for developing the “alternative
strategy” aimed to take the brakes off the anti-tumor
immune responses. The successful use of immune-
checkpoint inhibitors in clinical trials highlights the enor-
mous potentials of the immune system to efficiently react
against virtually any kind of tumor cell. The advantages in
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terms of significant antitumor activity, induction of long-
lasting responses, and favorable safety profile obtained with
the use of checkpoint inhibitors (anti-PD-1/PD-L1 anti-
bodies and anti-CTLA-4), definitely proved the concept
that the immune cellular responses may be pivotal to
regulate anti-cancer activities6,7.
Together with the check inhibition, the adoptive cell
therapy (ACT) with chimeric antigen receptor (CAR)
redirected T cells is perhaps the most attractive anti-
cancer strategy.
CARs encode for transmembrane chimeric molecules
with dual function: (a) immune recognition of tumor
antigens expressed on the surface of tumor cells; (b) active
promotion and propagation of signaling events control-
ling the activation of the lytic machinery. This system has
several advantages: (1) to provide “reprogrammed T-cells”
of an ex-novo activation mechanism; (2) to brake the
tolerance acquired by tumor cells, and (3) bypass
restrictions of the HLA-mediated antigen recognition,
over-stepping one of the barriers to a more widespread
application of cellular immunotherapy8.
Eshhar and coworkers were the first to demonstrate that
linking the scFv with the TCR ζ-chain or γ-chain for
signal transduction, provides T lymphocytes with Ab-type
specificity and activates all the functions of an effector
cell, including the production of IL-2 and the lysis of
target cells9. Since then, efforts have been dedicated to
produce a number of CARs designed to implement
quality, strength and duration of signals delivered by the
chimeric molecules. Variability in the functional proper-
ties has been obtained by engineering CARs expressing
the ζ-chain alone (1st generation) or in tandem with the
CD28 (2nd generation), or variably combined with a third
signaling domain (3rd generation), such as the 4-1BB
(CD137), the OX40 (CD134), ICOS and CD27, with the
idea to enhances T-cell proliferation, IL-2 secretion, sur-
vival and cytolytic activity. The 4th generation includes
“Armored CARs”, designed to increase persistence of
engineered T cells in tumor’s microenvironment.
Armored CARs combine the CAR functional activities
with the secretion of IL-2 or IL-12 expressed as an
independent gene in the same CAR vector10–18 (Fig.1).
Although the initial attempts to treat patients affected
by a variety of solid and liquid tumors, the breakthrough
with CAR-T cells therapy was achieved targeting B-cell
hematologic tumors.
The use of anti-CD19 CAR T cells have demonstrated
consistently high antitumor efficacy in children and adults
affected by relapsed B-cell acute lymphoblastic leukemia
(B-ALL), chronic lymphocytic leukemia, and B-cell non-
Hodgkin lymphoma, with percentage of complete remis-
sions ranging from 70 to 94% in the different trials19.
Based on these results, the FDA has approved two
immunotherapies with anti-CD19 modified T cells,
KYMRIAH [tisagenlecleucel (August 2017)] and YES-
CARTA [axicabtagene ciloleucel (October 2017)]. These
are now a second line treatment for patients up to 25
years of age with B-ALL (KYMRIAH) and for adults with
certain types of large B-cell lymphoma (YESCARTA).
Similar for the presence of an anti-CD19 murine scFv,
they signal through a different costimulatory domain
fused in tandem with the CD3 ζ-chain: 4-1BB for KYM-
RIAH, and CD28 for YESCARTA.
Other B-cell antigens have been targeted in preclinical
models, including CD20, CD22, CD23, ROR1, and the
kappa light chain. In principle, the treatment of B-cell
malignancies with CAR-T cells leads to almost entire B
cells repertoire depletion. In this case, the problems
derived by the disappearance of B cells from blood can be
partially mitigated by immunoglobulins administration.
However, depletion of other cell lineages might not be as
manageable, and the use of CAR-T cell therapies might be
restricted only to specific hematopoietic lineages. In
addition, large tumor masses clearance observed in these
trials was accompanied by acute and often severe
Fig. 1 Schematic representation of the chimeric antigen
receptors for adoptive cell therapy. CARs comprise an extracellular
domain with a tumor-binding moiety, typically a single-chain variable
fragment (scFv), followed by a hinge/spacer of varying length and
flexibility, a transmembrane (TM) region, and one or more signaling
domains associated with the T-cell signaling. The 1st CARs generation
is equipped with the stimulatory domain of the ζ-chain; in the 2nd
CARs generation the presence of costimulatory domains (CD28)
provides additional signals to ensure full activation; in the 3rd
generation an additional transducer domain (CD27, 41-BB or OX40) is
added to the ζ-chain and CD28 to maximize strength, potency, and
duration of the delivered signals; the 4th generation includes armored
CARs, engineered to synthetize and deliver interleukins (green ovals)
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syndrome requiring intensive care, following massive
release of cytokines from on-target activated T cells20–22.
CAR-T cells therapy for solid tumors
Less exciting conclusions can be derived from clinical
trials designed for the treatment of solid tumors with
engrafted CAR-T lymphocytes. Although from most of
the trials we do not have yet evaluable data, there is
enough proof to establish a solid platform for develop-
ment of CAR-T cells therapy for solid cancers. A good
clinical outcome depends on several parameters: (1)
choice of the target epitope; (2) CAR architecture; (3)
CAR-T cell doses, frequencies and way of administration
of CAR-T cells; (4) efficient tumor homing and long-term
survival in the tumor environment; (5) patients’ lympho-
depletion prior to the administration of CAR-T cells, and
subsequent cytokine support.
A key factor responsible for the poor specificity and
poor efficacy of CAR-T against malignant epithelial cells
is the lack of specific targetable antigens. An ideal target is
the signaling active splice variant of EGFR (EGFRvIII),
because specifically expressed on glioma cells and indis-
pensable for cell survival23. However, encouraging results
from early phase trials have been only obtained in neu-
roblastoma patients treated with anti-GD2 CAR-T cells,
and in ErbB2-positive sarcomas treatment24. Focus is now
on antigens preferentially expressed in certain types of
cancers (Table 1).
Few other factors, besides the differences in the chosen
targets, might be responsible for failure of CAR-T cell
therapies in solid tumors. The ACT in melanoma requires
more cells, more profound lymphodepletion and the use
of IL-2 support to obtain optimal results25–27. Further-
more, to exploit their cytotoxic function CAR-T lym-
phocytes need to overcome the limitations imposed by the
physical and functional barriers preserving epithelial and
mesenchymal compartments. Thus, in perspective, T cells
extravasation, tumor homing and persistence in a hostile
microenvironment are goals to be accomplished to
increase the chances of treating solid tumors with CAR-T
cell immunotherapy.
Extravasation
How to attract CAR-T lymphocytes to solid tumors
neoplastic lesions? In principle, activated T cells acquire
the expression of a cohort of homing molecules, including
E- and P-selectin ligands that mediate T cells rolling on
the endothelium, and subsequent chemokines receptors
engagement such as CXCR3, CXCL9, and CXCL10. The
interaction between chemokines receptors and their
ligands facilitates the expression of the LFA-1 and VLA-4
integrins, allowing cell adhesion through to ICAM-1 and
VCAM-1, respectively. These features have inspired the
engineering of CARs able to target components of the EC
matrix, such as αvβ6 integrin28 and VEGF receptor-2,
usually overexpressed on tumor vessels cells29. The idea
to target the tumor vascular environment responds to the
ability of neoplastic cells to drive angiogenic responses in
their favor. EC matrix-directed CAR-T cells would pos-
sibly be able to destroy the architecture of the neo-vessels
and likely limit the need for T cells to penetrate tumors.
Inefficient traffic
Trafficking of immune cells toward tumor foci is a
dynamic process controlled by a complex network of
interactions at multiple levels. The unbalanced secretion
of cytokines from tumor cells is one of the major issues
responsible for insufficient homing of CD8+ CXCR3high
T cells at the tumor side. Phenotypically mature T cells
express adhesion molecules and chemokines receptors
necessary for the interactions with endothelial cells. In
particular, the G protein-coupled receptors CXCR3 and
CCR5 are often expressed in active tumor-infiltrating
lymphocytes (TILs) from melanoma, breast and colorectal
cancers, indicating their importance in regulating T-cell
trafficking30. On the other hand, lack of expression of the
cognate ligands, CXCL9 and CXCL10 in many tumor cell
types hinders the recruitment of CD8+ effector and
memory T lymphocytes through chemokines receptors.
The tumor endothelium also constitutes a real barrier
against T-cell infiltration by overexpressing receptors and
ligands. During extravasation, T lymphocytes actively
degrade the main components of the sub-endothelial
membrane basement and the extracellular matrix,
including heparan sulphate proteoglycans (HSPGs)31.
Therefore, CAR-T cells attacking solid tumors must be
able to degrade HSPGs by releasing heparanase (HPSE) to
access tumor cells. Recent studies have shown that HPSE
deficiency in in vitro-engineered and cultured tumor-
specific T cells may limit their antitumor activity in
stroma-rich solid tumors32.
Tumor microenvironment
To make matters worse, the tumor microenvironment is
inhospitable and inaccessible to the invasion of immune
cells, because of hypoxia, low nutrients, and for the
metabolic acids high concentration that make T cells
unable to proliferate and produce cytokines. The absence
of important amino acids such as tryptophan, lysine, and
arginine, is responsible for the autophagic processes and
stress responses activation, inducing T cells to exploit the
resources of intracellular nutrients. Immunosuppressive
roles have been ascribed to numerous substances pro-
duced by tumor and immune cells. Prostaglandin E2
(PGE2) and adenosine are released in large quantities by
cancer cells and macrophages in hypoxic conditions, and
inhibit T lymphocytes proliferation by activating G
protein-coupled receptors and protein kinase A.
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Table 1 Summary of the targetable tumor antigens selected for CAR-T cell-based immunotherapy in epithelial
malignancies (from http:/clinicaltrials.gov)
Target antigen Disease tumor CAR-T Gene transfer Reference Identifier
CEA Colorectal carcinoma CD28/CD3ζ LV/RV 94, 95 NCT03267173—NCT00673322
Breast cancer NCT00673829—NCT02850536
Liver metastases
EGFR Glioma—NSCL cancer 4-1BB/CD3ζ LV 96 NCT03182816–NCT03152435
NCT02331693–NCT01869166
EGFRvIII Glioma—Glioblastoma CD28/4-1BB/CD3ζ LV/RV 97, 98 NCT03267173–NCT03170141
NCT02844062–NCT02664363
NCT01454596
EphA2 Glioma NA NA NCT02575261
EpCAM Carcinomasa CD28/CD3ζ LV NCT03013712–NCT02729493
NCT02725125–NCT02915445
ErbB2 Carcinomasb CD28/CD3ζ RV 24, 47, 99, 100 NCT03267173–NCT02713984
NCT02547961–NCT01935843
FAP Mesotelioma CD28/CD3ζ RV 101 NCT01722149
FR-α Ovarian carcinoma FcεR1 γ RV 102 NCT03185468–NCT00019136
GD2 Neuroblastoma CD28/CD3ζ/OX40 RV 103, 104 NCT03356795–NCT02919046
NCT02765243–NCT02761915
NCT01822652
GPC3 Lung squamous cell carcinoma NA NA NCT03198546–NCT03084380
Hepatocellular carcinoma NCT02905188–NCT02876978
NCT02723942–NCT02395250
IL13-Rα2 Glioma 4-1BB/CD3ζ LV 105 NCT02208362
Mesothelin Metastatic cancer 4-1BB/CD3ζ LV/RV RNA-EP 106 NCT03356795–NCT03323944
Pleural mesothelioma NCT03267173–NCT03182803
Pancreatic carcinoma NCT02930993–NCT02792114
Breast carcinoma NCT02580747–NCT02465983
Lung cancer NCT02388828–NCT01897415
NCT01583686
MUC1 Carcinomasc CD28/4-1BB/CD3ζ LV 107 NCT03356808–NCT03356795
NCT03267173–NCT03198052
NCT02617134–NCT02587689
MUC16 Ovarian carcinoma CD28/CD3ζ-IL-12 NA 108 NCT02498912
PSMA Prostate cancer CD28/CD3ζ RV 109 NCT03185468–NCT03089203
NCT01140373
ROR1 Breast lung carcinoma NA NA NCT02706392
VEGFR-II Metastatic cancer NA RV NCT01218867
Melanoma
Renal cancer
LV lentiviral, RV retroviral, NA not available
aGastric cancer—colon carcinoma—hepatocellular carcinoma—pancreatic carcinoma—prostate cancer—esophageal carcinoma
bGlioblastoma—glioma—sarcoma—head and neck squamous cell carcinoma—breast cancer—ovarian cancer—gastric cancer—lung cancer—pancreatic carcinoma
cGastric cancer—lung cancer—pancreatic carcinoma—breast cancer—glioma—colorectal carcinoma—hepatocellular carcinoma
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Moreover, tumor infiltrate is enriched in Tregs, myeloid-
derived suppressor cells (MDSC), TAM and TAN (tumor-
associated macrophages and tumor-associated neu-
trophils) favoring tumor survival by the secretion of TGF-
β, IL-10, nitric acid, and indoleamine dioxygenase 2–3.
CD4+/FOXP3+ Tregs are suppressor T lymphocytes able
to down-modulate immune effector cells activities
through multiple mechanisms, including cell–cell contact
inhibition and release of soluble factors such as TGF-β
and IL-1033. To counteract these immunomodulatory
activities, CAR-T lymphocytes resistant to TGF-β sup-
pression have been generated by the expression of a
dominant negative TGF-β receptor, demonstrating their
superior antitumor activity in animal models34.
Tumor cells, TILs and immature myeloid cells, are
responsible for a large part of ROS production35, which
can downmodulate CD3-ζ receptor levels, making TCR-
mediated T-cell activation less efficient36,37. The peculiar
aspects of the tumor milieu rich of inflammatory activity
provided the rational for constructing CAR-T cells
expressing catalase to reduce H2O2 and counteract the
ROS-induced unresponsiveness of these and bystander
cells38.
IL-4 is another immunosuppressive cytokine that
synergizes with IL-10 and TGF-β and promotes activation
of macrophages into M2 cells. IL-4’s suppressive effect
can be converted into stimulatory effects by chimeric
receptors that, engineered to express the IL-4 receptor
ectodomain, generate active signals mimicking the IL-2 or
IL-7 receptors39,40. CAR-T cells expressing “switch” CARs
have shown improved capacity to kill TAA-expressing
tumor cells41,42.
Positive inputs come from experimental use of
“Armored CAR” in solid tumor cell therapy. TRUCKS (T
cell Redirected Universal Cytokine killing) are engineered
to release IL-12 with the intent to mitigate the tumor
microenvironment hostile activity. Notably, IL-12
enhances recruitment and functions of innate immunity
cells, with the consequence of antigen negative cancer
cells increased destruction42,43.
Despite Armored CARs have demonstrated superior
anti-tumor activity in xenograft models compared to con-
ventional CAR-T, the abundant production of cytokines
often results in a severe cytokine release syndrome (CRS)
without particular increased efficacy in clinical trials18.
“Safety” and “efficacy”: the two checkpoints of
CAR-T cell therapy
The critical point of ACT with chimeric receptors is the
need to control unwanted immunological CAR-T cells
responses. CAR-T cell therapy’s efficacy is largely coun-
teracted by the occurrence of toxicity, sign at the same
time of good performing T-cell activity. For this reason,
“safety” and “efficacy” are hallmarks for the improvement
of CAR-T cell therapy, and their harmonization will
require combination with other therapeutic approaches,
to effectively treat solid tumors44.
CRS is occurring in almost 80% of the patients treated
with anti-CD19 CAR-T cells and can be fatal or life
threatening20,45. Symptoms include transient neurologic
toxicity, febrile neutropenia, cytopenia not resolved by day
28, and infections. This is mostly due to massive release of
tumor cell components in the blood for rapid destruction
of a large tumor mass (“on-target/on-tumor” toxicity), and
to pro-inflammatory cytokines released by CAR-T cells,
vascular endothelial cells, and others, resulting in mono-
cyte and macrophage activation with the risk of multiple
organ failure.
While CRS can be devastating in course of treatment of
liquid tumors, the risk for “on-target/on-tumor” toxicity
for solid tumor seems to be lower. This can be at least
partially explained by the different stoichiometry in
effector-target cell composition reachable in liquid rather
than solid tumors, ensuring target killing in a relatively
short time. Secondly, the magnitude of CRS correlates
with the tumor burden20,46.
The other form of toxicity is the on-target/off-tumor
toxicity. This is related to the difficulty to identify tumor-
specific cell-surface molecules targetable by CAR-T cells
without serious side effects. Most antigens are not tumor
selective and, particularly in solid tumors, tend to be
merely overexpressed. Furthermore, cancer cells redefine
over time density and stoichiometry of antigen receptors,
with significant implication in predicting the safety pro-
file. For these reasons, the risk of an on-target/off-tumor
toxicity is higher in solid tumors and, at least in one case,
severity of this reaction may have caused patient death47.
In principle, toxicity can be controlled at several levels.
One way is to administer required numbers of cells
through two (30+ 70)% or three doses (10+ 30+ 60)%,
possibly using RNA transiently-engineered CAR-T cells in
the first administration to minimize the on-target off-
tumor activity48–50. Another way is to start the treatment
at the earlier stages of tumor development, before the
number of cancer cells becomes too high.
The need to minimize on- and off-tumor’s reactivity, is
the major criterion orienting the conceptual design of dual
CAR-T antigen recognition. At least two types of approa-
ches are currently under investigation. In the first
approach, target selectivity is ensured by a double recog-
nition of two tumor antigens expressed by the same cell,
while the second strategy implies the design of inhibitor
chimeric antigen receptors called iCARs, able to divert
CAR-T cells activity from normal tissues51,52 (Fig. 2).
Tandem CAR
In the first case, the dual recognition of different epi-
topes by two CARs diversely designed to either deliver
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killing (i.e. through ζ-chain) or costimulatory signals (i.e.,
through CD28) allows a superior activation of the
reprogrammed T cells. Consequently, this is a safer path
restricting Tandem CAR’s activity to cancer cell expres-
sing simultaneously two antigens rather than one. In this
case, the potency of delivered signals in engineered T cells
will remain below threshold of activation and thus inef-
fective in absence of the engagement of costimulatory
receptor (CCR)53. More importantly, this strategy is
potentially suitable to control the on-target/off-tumor
toxicity, because the combinatorial antigen recognition
enhances selective tumor eradication and protects normal
tissues expressing only one antigen from unwanted
reactions. In refined strategies for fine-tuning of signals,
CARs can be designed to provide weaker strength of
activation, while CCR can be equipped with modules for
stronger costimulation. The mechanism of dual antigen
recognition is also utilized by T lymphocytes in secondary
lymphoid organs where T cells receive both activating and
costimulatory signals necessary to bust their activity and
to sustain their life span during recirculation54.
Inhibitory CAR
Inhibitory CARs (iCARs) are designed to regulate CAR-
T cells activity through inhibitory receptors signaling
modules activation, typically utilized by T lymphocytes to
mitigate the immune responses. This approach combines
the activity of two chimeric receptors, one of which
generates dominant negative signals limiting the respon-
ses of CAR-T cells activated by the activating receptor.
iCARs can switch off the response of the counteracting
activator CAR when bound to a specific antigen expressed
only by normal tissues. In this way, iCARs-T cells can
distinguish cancer cells from healthy ones, and reversibly
block functionalities of transduced T cells in an antigen-
selective fashion (Fig. 2).
In human T lymphocytes, PD-1 and CTLA-4 are inhi-
bitor receptors that reversibly control reduction of TCR
signaling potency and can be utilized to mitigate the
activation of chimeric receptors. CTLA-4 or PD-1 intra-
cellular domains in iCARs trigger inhibitory signals on T
lymphocytes, leading to less cytokine production, less
efficient target cell lysis, and altered lymphocyte moti-
lity55. Critical for the efficacy of iCAR-T cell therapy is
antigens selection, because the anti-tumor activity would
depend on tissue distribution and stoichiometry between
normal and tumor antigens on target cells.
Gene delivery
An important aspect is the vector’s choice for trans-
ferring genes in T lymphocytes. The ideal carrier must
meet criteria of efficacy, delivery, and safety. The most
used carriers are retroviral (RV) and lentiviral (LV)56–58.
Both RV and LV systems account for excellent gene
Fig. 2 Simultaneous targeting of two antigens may serve to enhances (Tandem CAR) or cut down (iCAR) the activity of the CAR-T cells.
Tandem CARs (TanCAR) mediate bispecific activation of T cells through the engagement of two chimeric receptors designed to deliver stimulatory or
costimulatory signals in response to an independent engagement of two different tumor associated antigens (TAAs). iCARs use the dual antigen
targeting to shout down the activation of an active CAR through the engagement of a second suppressive receptor equipped with inhibitory
signaling domains
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transduction efficiency, but differ for the ability to infect
resting rather than dividing cells, and for the integration
mechanisms that favor privileged areas of the genome
rather than others56–60.
The ability of LV-based vectors to integrate transgenes
in non-replicating cells reduces time of ex vivo cell
manipulation, with the advantage of obtaining T lym-
phocytes with a “young” and poorly differentiated phe-
notype, optimal for therapeutic purposes61.
However, the preparation of viral particles for gene
therapy remains tedious and carries the risks of con-
tamination by infectious agents, including the replication-
competent virus generated by the recombination between
vector and packaging cell lines.
The major clinical problems related to the usage of RVs
and LVs are the development of innate immune and
inflammatory responses to viral vectors62,63, and the risk
linked to preferential integration near promoters or
transcriptional units, with increased chances of causing
adverse effects57–60.
Alternative to viral systems are the transposons Piggy-
Bac (PB) and Sleeping Beauty (SB), allowing integration of
large DNA sequences between two ITRs in the host
genome by a “cut and paste” transposase’s mechanism64
(Fig. 3). The use of transposons in gene therapy would be
advantageous for several reasons: simplicity of gene
transduction (can be introduced into T cells by nucleo-
fection), safety for both patients and operators, less
complexity, minor cost, and less GMP requirements. PB
and SB allow excellent standard of gene expression and
integration in absence of foreign proteins that can elicit
adverse reactions (Fig. 4). Furthermore, since the trans-
position mechanisms do not involve reverse transcription,
transposon vectors are not prone to incorporating
mutations and eliminate the risk of rearrangements of the
expression cassette that integrates into chromosomal
DNA in an intact form65,66.
Substantial improvement of these techniques has been
demonstrated with the introduction of SB-transposition
from minimalistic DNA vectors called Minicircles (MCs).
MCs offer more stability, superior gene expression, and
less toxicity to T cells compared to SB plasmids67,68. The
integration profile of a CD19-CAR mobilized through
MCs resulted to be highly favorable displaying a near-
random integration pattern, in contrast to LVs that prefer
for transcriptionally active genes69. Several clinical trials
in phase I and II are ongoing with SB-generated CD19
CAR-T cells70, and one with MUC1-CAR for metastatic
breast cancer is currently under review (US-1360).
The problem of target loss and antigen escape
An emerging threat to CAR-T immunotherapy is the
antigen escape that makes CAR-T cells inefficient against
cancer cells. CAR-T cells tumor sculpting exerts a
selective pressure involving the selection of antigen-
negative cells over time. This phenomenon has been
described in many clinical studies, including glioblastoma
trial with anti-ErbB2-CAR71. Appearance of Ag-negative
cells limits per se the efficacy of immune therapy, high-
lighting the importance of developing approaches that
quickly allow targeting other antigens at the appearance
of the new neoplastic phenotype.
Flexibility to the limitation of having one CARs for one
antigen has been illustrated in the seminal work of
Tamada et al. describing a 3rd generation CAR equipped
with an scFv able to bind FITC-labeled monoclonal
antibodies directed against tumor antigens72. In this case,
the anti-FITC CAR-T lymphocytes were able of efficient
target lysis, T-cell proliferation, and cytokine production.
This strategy has been refined by Clemenceau and
colleagues by engineering an FcγRIIIa-158(V/V)-FcεRIγ
chimeric receptor able to bind any mAb directed against
any cancer cell surface antigen73. The idea is to combine
the therapeutic activity of monoclonal antibodies utilized
in cancer therapy with the recruitment of cellular com-
ponents of the immune system (Fig. 5). The proof of
concept has been validated in other laboratories by Kudo
K., Ochi F., and D’Aloia MM., engineering CD16-CRs able
to complex IgGs with an extracellular FcγRIII binding
domain and to deliver biochemical signals through either
4-1BB/ζ-chain or 28-ζ-chain74–76. Their FcγRIIIa CRs
were able to trigger antibody-dependent cytotoxicity
(ADCC)-like activity in transduced T lymphocytes against
opsonized CD20+ lymphoma cells, in vitro or when
injected in NOD-scid-IL2rgnull mice in presence of
rituximab.
Further advantage of this strategy is the possibility to
control unwanted reactions by the administration of high
doses of immunoglobulins that might compete with the
FcγR for binding. Moreover, the clearance of the anti-
bodies from blood in about three weeks would offer a
further level of control for CD16-CR-T cells activity,
protecting patients from GVH reactions. On the other
hand, the use of CD16-CR-T cells might be limited by the
competition of therapeutic mAbs with serum immu-
noglobulins for binding to the FcγR-CRs, thus hampering
their ability to mediate ADCC. Further restrictions to
their usage can be hypothesized for patients affected by
autoimmune diseases or diseases mediated by cross-
reacting antibodies. In both cases, the high levels of self-
reacting Abs might redirect engineered T cells against
self-antigens.
Genome editing
The rapid advancement of genome-editing techniques
holds much promise in the field of human gene therapy.
By delivering the Cas9 protein and appropriate guide
RNAs into cells, the genome can be cut at any desired
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Fig. 3 The Transposon systems of Sleeping Beauty (SB) and PiggyBac (PB) for gene delivery. Transposition is possible through a dual vector
system that comprises the transposon containing the transgene flanked by two inverted terminal repeats, and a transposase that mobilizes the
transposon. The CAR is integrated into the genome through a cut-and-paste mechanism SB transposon vectors are characterized by the presence of
specular IR/DR sequences, target for the transposase. The SB vector contains the gene of interest (CAR). The SB transposase (SB-100×) binds to the IR/
DR sequences and cuts the vector to release the transposable portion of DNA. TA sequences in the host DNA act as acceptors of the transposed
element. The PB transposon is a mobile genetic element that transposes the gene of interest (CAR) from the vector to the host DNA. The l’hyperactive
PiggyBac (Hy7 PB) transposase recognizes the transposon-specific “inverted terminal repeats” sequences (ITRs) located at the ends of the gene of
interest. Transposition occurs between two TTAA acceptor sites located in the host DNA
Fig. 4 Comparison of viral versus transposon-based gene delivery systems. Plasmid-based transposon systems combine the advantages of
integrating viral vectors with those of non-viral delivery systems
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location, disrupting or changing the sequence of specific
genes with the intent to generate armed lymphocytes with
increased capabilities of extravasation and survival in
tumor microenvironment, or with less potential of
toxicity.
Currently, three classes of gene-editing proteins are
available: Zinc-Finger, TALENs (Transcription Activator-
Like Effector Nucleases), and CRISPR/Cas9 (Clustered
Regularly Interspaced Palindromic Repeats/CRISPR-
associated-9)77,78. Each of them can guide the insertion of
the gene of interest in desired sites through the binding of
user-defined DNA or RNA sequences, inducing a double-
stranded DNA break.
Genome editing has been used to disrupt the TCR
complex by targeting either TRAC or TRBC to make T
lymphocytes defective of endogenous TCR, less prone to
induce off-tumor reactivity in the form of GVHD78,79.
Also interesting are the knockout of PD-180 and CTLA-4
genes regulating the T-cell checkpoint inhibitors and the
silencing of DGK in the TGF-β pathway, made to create
the most resistant lymphocytes to immunosuppressive
stimuli, including those from tumor microenvironment81.
Another possibility is to guide the insertion of trans-
genes in specific genome sites without affecting endo-
genous gene structure or expression. Extra-genic regions
of the genome called “safe harbors” (GSH) could be able
to accommodate the expression of newly integrated DNA
without generating adverse effects on the host cell. Three
intragenic sites have been proposed as safe harbors
(AAVS1, CCR5, and ROSA26) although all of them are in
fairly gene-rich regions and are near genes that have been
implicated in cancer82.
Concluding remarks
Although majority of CAR T-cell clinical trials are
conducted in the setting of hematological malignancies,
solid-tumor oncology represents an urgent clinical need.
Besides the difficulties of how to reprogram T cells to
drive them to tumor sites and survive in the micro-
environment, there are few other issues that become more
compelling in the perspective of solid tumors CAR-T cells
treatment.
One of the major questions would be: which is the best
solid tumor to target? The target antigen specificity is a
solid selection criterion. As mentioned, the rational for
CAR-T cell therapy of glioblastoma is the peculiar expres-
sion of the highly specific EGFRvIII antigen in this tumor.
Cancer immunotherapy widely relies on the adminis-
tration of mAbs directed against signaling receptors or
tumor antigens. However, their efficacy and clinical suc-
cess largely depends on the presence of immune effector
cells with ADCC activity in the tumor infiltrate, including
NK cells83–87. This raises few considerations. It is neces-
sary to identify cancer types where the conspicuous pre-
sence of immune cells in the tumor microenvironment
would indicate a relative permissive status for engrafted
T cells to rich tumor foci and possibly be effective against
cancer cells88-90. To this extent, several studies have
demonstrated that the mutational load and the frequency
of neoantigens correlates with the response to
Fig. 5 In the CD16-CR, the chimeric receptor extracellular portion is engineered to express an FcγR domain able to complex virtually any
mAb directed against TAAs expressed by malignant cells. The FcγR module is combined to a hinge region, a transmembrane domain, and to the
intracellular signaling domains of the ζ-chain and CD28. Advantages and disadvantages of the CD16-CR are illustrated
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immunotherapy in melanoma, lung, and microsatellite
instability (MSI)-positive colorectal cancers91,92. It is not
singular mutations that predict patients’ clinical outcome,
but the presence of a high number of mutations and
global T-cell responses in the tumor microenvironment.
The second is that strategies aimed to combine ther-
apeutic activities of the mAbs used with the potential of a
T cell-dependent activation at the tumor site might be
ideal. FcγR-CRs can target more than one antigen,
sequentially or in combination, thus limiting the risk of
immune escape due to emergence or outgrowth of
antigen-null tumor cells. However, no clinical trials have
been conducted to date to test any of these hypotheses.
Another aspect defining CAR T-cell activity is the affi-
nity for the antigen. High-affinity binding enables CAR
driven T-cell effector responses against target cells
expressing relatively low levels of antigen93. This impacts
on a variety of adverse effects occurring immediately or
weeks after CAR-T infusion, and there is need as well to
invest more research in this field to improve control of
off-target toxicity.
There is also the need to implement strategies to con-
trol life span of engineered T cells. CAR-T cells can
persist and even expand over time, with the consequence
of mediating their effects, both therapeutic and deleter-
ious. The introduction of cellular switches to eliminate
CAR-T cells in case of adverse events is therefore safe and
recommended.
As a final consideration, CAR-T technologies should be
validated in preclinical settings using immune competent
animals. The immunocompromised mice models cannot
recapitulate the immunomodulatory effects of the hosts
endogenous immune system, including pathological
responses such as CRS, or the immunosuppressive effects
generated by the tumor microenvironment on adoptively
transferred T cells.
We believe the effectiveness of these living drugs in
treating late-stage liquid cancers raised the exciting pos-
sibility of a breakthrough approach in cancer therapy, but
it needs to be shaped and refined to be impactful in the
treatment of solid tumors.
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